ADC Therapeutics - ADCT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.00
  • Forecasted Upside: 357.26 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$5.03
▼ -0.21 (-4.01%)

This chart shows the closing price for ADCT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ADC Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADCT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADCT

Analyst Price Target is $23.00
▲ +357.26% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for ADC Therapeutics in the last 3 months. The average price target is $23.00, with a high forecast of $44.00 and a low forecast of $5.00. The average price target represents a 357.26% upside from the last price of $5.03.

This chart shows the closing price for ADCT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in ADC Therapeutics. This rating has held steady since June 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/13/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/12/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/10/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/8/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/8/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/7/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/21/2022JPMorgan Chase & Co.Initiated CoverageOverweight$5.00Low
9/19/2022HC WainwrightBoost TargetBuy$20.00 ➝ $21.00Low
9/9/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$17.00 ➝ $11.00Low
8/22/2022HC WainwrightLower TargetBuy$44.00 ➝ $20.00Low
7/11/2022HC WainwrightLower TargetBuy$54.00 ➝ $44.00N/A
5/23/2022HC WainwrightReiterated RatingBuy$54.00Low
4/12/2022Morgan StanleyBoost TargetOverweight$29.00 ➝ $30.00High
3/4/2022HC WainwrightLower TargetBuy$55.00 ➝ $54.00High
2/1/2022Morgan StanleyLower TargetOverweight$47.00 ➝ $29.00High
11/8/2021Wolfe ResearchInitiated CoverageOutperform$44.00Low
11/4/2021HC WainwrightReiterated RatingBuyLow
11/3/2021Royal Bank of CanadaBoost TargetOutperform$33.00 ➝ $34.00Medium
9/7/2021Morgan StanleyLower TargetOverweight$51.00 ➝ $47.00Low
8/10/2021HC WainwrightReiterated RatingBuy$55.00Low
8/9/2021Royal Bank of CanadaInitiated CoverageOutperform$33.00High
7/16/2021Morgan StanleyLower TargetOverweight$53.00 ➝ $51.00Low
6/15/2021Cantor FitzgeraldInitiated CoverageOverweight$46.00Medium
5/14/2021HC WainwrightLower TargetBuy$57.00 ➝ $55.00High
5/10/2021Morgan StanleyLower TargetOverweight$55.00 ➝ $53.00High
4/26/2021HC WainwrightBoost TargetBuy$48.00 ➝ $57.00High
3/23/2021Morgan StanleyLower TargetOverweight$56.00 ➝ $55.00Medium
3/19/2021HC WainwrightBoost TargetBuy$47.00 ➝ $48.00High
12/16/2020Morgan StanleyBoost TargetOverweight$52.00 ➝ $56.00Medium
12/2/2020Stifel NicolausInitiated CoverageHold$42.00High
10/29/2020HC WainwrightInitiated CoverageBuy$47.00Low
10/13/2020Morgan StanleyLower TargetOverweight$53.00 ➝ $52.00Low
6/9/2020Morgan StanleyInitiated CoverageOverweight$53.00High
6/9/2020CowenInitiated CoverageOutperformHigh
6/9/2020Bank of AmericaInitiated CoverageBuy$45.00High
(Data available from 10/5/2017 forward)

News Sentiment Rating

0.41 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
3/9/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/8/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
5/8/2022
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/7/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/7/2022
  • 1 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
8/6/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
9/5/2022
  • 1 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/5/2022

Current Sentiment

  • 1 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
ADC Therapeutics logo
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Read More

Today's Range

Now: $5.03
Low: $4.88
High: $5.08

50 Day Range

MA: $6.76
Low: $4.66
High: $10.30

52 Week Range

Now: $5.03
Low: $4.58
High: $32.00

Volume

8,187 shs

Average Volume

230,828 shs

Market Capitalization

$386.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.28

Frequently Asked Questions

What sell-side analysts currently cover shares of ADC Therapeutics?

The following sell-side analysts have issued reports on ADC Therapeutics in the last twelve months: HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Royal Bank of Canada, and Wolfe Research.
View the latest analyst ratings for ADCT.

What is the current price target for ADC Therapeutics?

5 Wall Street analysts have set twelve-month price targets for ADC Therapeutics in the last year. Their average twelve-month price target is $23.00, suggesting a possible upside of 357.3%. Wolfe Research has the highest price target set, predicting ADCT will reach $44.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $5.00 for ADC Therapeutics in the next year.
View the latest price targets for ADCT.

What is the current consensus analyst rating for ADC Therapeutics?

ADC Therapeutics currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ADCT will outperform the market and that investors should add to their positions of ADC Therapeutics.
View the latest ratings for ADCT.

What other companies compete with ADC Therapeutics?

How do I contact ADC Therapeutics' investor relations team?

The company's listed phone number is 41-21-653-0200 and its investor relations email address is [email protected] The official website for ADC Therapeutics is www.adctherapeutics.com. Learn More about contacing ADC Therapeutics investor relations.